March 10, 2025
Envol Biomedical is thrilled to welcome Jennifer Cleerdin as our new Director of Quality and Regulatory Services. With over two decades of experience in regulatory compliance and laboratory practices, Jennifer brings a wealth of expertise to Envol at a pivotal time in our company’s evolution. Her leadership will be instrumental as we introduce Good Laboratory Practices (GLP) initiatives later this year—a transformative step for Envol and our clients engaged in Non-Human Primate (NHP) research in the United States.
Paving the Way for GLP Compliance at Envol Biomedical
Envol has long been a trusted provider of NHP testing, and the introduction of GLP compliance marks a major milestone in our journey. GLP standards ensure that research conducted in our facility meets the rigorous documentation, personnel training, and infrastructure requirements necessary for regulatory submissions to agencies such as the U.S. Food and Drug Administration (FDA). By achieving GLP compliance, Envol is expanding its capabilities to support the development of life-saving therapeutics with an added layer of reliability and scientific integrity.
As Jennifer says, “GLP compliance opens up an entirely new world of possibilities for business. It allows us to be an integral part of the drug discovery pipeline, ensuring our research meets the highest standards required for regulatory approval.”
What GLP Means for NHP Testing
While Envol Biomedical and our partners have extensive experience in NHP research, adopting GLP protocols will refine and elevate our processes. The transition to a GLP environment introduces a new level of oversight, including defined roles such as study directors and testing facility managers, stringent training requirements, and enhanced documentation practices. These changes not only enhance internal operational efficiencies but also provide our clients with the assurance that their studies are conducted in full compliance with regulatory expectations.
A Leader with a Vision
Jennifer Cleerdin’s background uniquely positions her to lead Envol through this transition. Having previously established GLP programs at Lovelace Biomedical and serving in various leadership roles within contract research and manufacturing organizations, Jennifer has dedicated her career to ensuring scientific excellence through regulatory adherence. Her long-standing professional relationship with Envol CEO Dr. Jake McDonald played a role in her decision to join the team, as she recognized the company’s commitment to quality, innovation, and a forward-thinking approach.
“I’ve never seen a team so eager and willing to learn GLP and adapt to a regulated environment,” Jennifer shared. “Their unstoppable mentality and enthusiasm for this shift reaffirmed my decision to be a part of Envol. I initially joined to bridge a gap, but I’ve completely fallen in love with the company and its people.”
Looking Ahead: June 2025 GLP Launch
The Envol team is actively preparing for full GLP compliance, with a target launch date of June 2025. Ongoing mock studies are helping to refine processes and ensure a seamless transition into this new regulatory framework. For our clients, this means access to top-tier, compliant research that will better support their drug development goals.
Envol Biomedical remains committed to providing the highest quality research solutions for our customers. With the introduction of GLP compliance and the addition of Jennifer Cleerdin to our leadership team, we are setting new standards for excellence in NHP research. Stay tuned for more updates as we move toward our official GLP launch! If you are interested in learning more about how Envol’s enhanced capabilities can support your research, feel free to contact us today.
